Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

NCT02654080 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: HIV-1 nef/tat/vif, env pDNA vaccine
BIOLOGICAL: rVSV HIV envC vaccine
BIOLOGICAL: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)